Cargando…

Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

BACKGROUND: Although clear evidence shows that chronic kidney disease is a predictor of cardiovascular events, death, and accelerated coronary artery disease (CAD) progression, it remains unknown whether CAD is a predictor of progression of chronic kidney disease to end‐stage renal disease. We sough...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabe, Marwa A., Claggett, Brian, Burdmann, Emmanuel A., Desai, Akshay S., Ivanovich, Peter, Kewalramani, Reshma, Lewis, Eldrin F., McMurray, John J. V., Olson, Kurt A., Parfrey, Patrick, Solomon, Scott D., Pfeffer, Marc A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859277/
https://www.ncbi.nlm.nih.gov/pubmed/27108247
http://dx.doi.org/10.1161/JAHA.115.002850
_version_ 1782430941422026752
author Sabe, Marwa A.
Claggett, Brian
Burdmann, Emmanuel A.
Desai, Akshay S.
Ivanovich, Peter
Kewalramani, Reshma
Lewis, Eldrin F.
McMurray, John J. V.
Olson, Kurt A.
Parfrey, Patrick
Solomon, Scott D.
Pfeffer, Marc A.
author_facet Sabe, Marwa A.
Claggett, Brian
Burdmann, Emmanuel A.
Desai, Akshay S.
Ivanovich, Peter
Kewalramani, Reshma
Lewis, Eldrin F.
McMurray, John J. V.
Olson, Kurt A.
Parfrey, Patrick
Solomon, Scott D.
Pfeffer, Marc A.
author_sort Sabe, Marwa A.
collection PubMed
description BACKGROUND: Although clear evidence shows that chronic kidney disease is a predictor of cardiovascular events, death, and accelerated coronary artery disease (CAD) progression, it remains unknown whether CAD is a predictor of progression of chronic kidney disease to end‐stage renal disease. We sought to assess whether CAD adds prognostic information to established predictors of progression to dialysis in patients with chronic kidney disease, diabetes, and anemia. METHODS AND RESULTS: Using the previously described Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) population, we compared baseline characteristics of patients with and without CAD. Cox proportional hazards models were used to assess the association between CAD and the outcomes of end‐stage renal disease and the composite of death or end‐stage renal disease. Of the 4038 patients, 1791 had a history of known CAD. These patients were older (mean age 70 versus 65 years, P<0.001) and more likely to have other cardiovascular disease. CAD patients were less likely to have marked proteinuria (29% versus 39%, P<0.001), but there was no significant difference in estimated glomerular filtration rate between the 2 groups. After adjusting for age, sex, race, estimated glomerular filtration rate, proteinuria, treatment group, and 14 other renal risk factors, patients with CAD were significantly more likely to progress to end‐stage renal disease (adjusted hazard ratio 1.20 [95% CI 1.01–1.42], P=0.04) and to have the composite of death or end‐stage renal disease (adjusted hazard ratio 1.15 [95% CI 1.01–1.30], P=0.03). CONCLUSIONS: In patients with chronic kidney disease, diabetes, and anemia, a history of CAD is an independent predictor of progression to dialysis. In patients with diabetic nephropathy, a history of CAD contributes important prognostic information to traditional risk factors for worsening renal disease.
format Online
Article
Text
id pubmed-4859277
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48592772016-05-20 Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Sabe, Marwa A. Claggett, Brian Burdmann, Emmanuel A. Desai, Akshay S. Ivanovich, Peter Kewalramani, Reshma Lewis, Eldrin F. McMurray, John J. V. Olson, Kurt A. Parfrey, Patrick Solomon, Scott D. Pfeffer, Marc A. J Am Heart Assoc Original Research BACKGROUND: Although clear evidence shows that chronic kidney disease is a predictor of cardiovascular events, death, and accelerated coronary artery disease (CAD) progression, it remains unknown whether CAD is a predictor of progression of chronic kidney disease to end‐stage renal disease. We sought to assess whether CAD adds prognostic information to established predictors of progression to dialysis in patients with chronic kidney disease, diabetes, and anemia. METHODS AND RESULTS: Using the previously described Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) population, we compared baseline characteristics of patients with and without CAD. Cox proportional hazards models were used to assess the association between CAD and the outcomes of end‐stage renal disease and the composite of death or end‐stage renal disease. Of the 4038 patients, 1791 had a history of known CAD. These patients were older (mean age 70 versus 65 years, P<0.001) and more likely to have other cardiovascular disease. CAD patients were less likely to have marked proteinuria (29% versus 39%, P<0.001), but there was no significant difference in estimated glomerular filtration rate between the 2 groups. After adjusting for age, sex, race, estimated glomerular filtration rate, proteinuria, treatment group, and 14 other renal risk factors, patients with CAD were significantly more likely to progress to end‐stage renal disease (adjusted hazard ratio 1.20 [95% CI 1.01–1.42], P=0.04) and to have the composite of death or end‐stage renal disease (adjusted hazard ratio 1.15 [95% CI 1.01–1.30], P=0.03). CONCLUSIONS: In patients with chronic kidney disease, diabetes, and anemia, a history of CAD is an independent predictor of progression to dialysis. In patients with diabetic nephropathy, a history of CAD contributes important prognostic information to traditional risk factors for worsening renal disease. John Wiley and Sons Inc. 2016-04-23 /pmc/articles/PMC4859277/ /pubmed/27108247 http://dx.doi.org/10.1161/JAHA.115.002850 Text en © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Sabe, Marwa A.
Claggett, Brian
Burdmann, Emmanuel A.
Desai, Akshay S.
Ivanovich, Peter
Kewalramani, Reshma
Lewis, Eldrin F.
McMurray, John J. V.
Olson, Kurt A.
Parfrey, Patrick
Solomon, Scott D.
Pfeffer, Marc A.
Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
title Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
title_full Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
title_fullStr Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
title_full_unstemmed Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
title_short Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
title_sort coronary artery disease is a predictor of progression to dialysis in patients with chronic kidney disease, type 2 diabetes mellitus, and anemia: an analysis of the trial to reduce cardiovascular events with aranesp therapy (treat)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859277/
https://www.ncbi.nlm.nih.gov/pubmed/27108247
http://dx.doi.org/10.1161/JAHA.115.002850
work_keys_str_mv AT sabemarwaa coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT claggettbrian coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT burdmannemmanuela coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT desaiakshays coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT ivanovichpeter coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT kewalramanireshma coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT lewiseldrinf coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT mcmurrayjohnjv coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT olsonkurta coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT parfreypatrick coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT solomonscottd coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat
AT pfeffermarca coronaryarterydiseaseisapredictorofprogressiontodialysisinpatientswithchronickidneydiseasetype2diabetesmellitusandanemiaananalysisofthetrialtoreducecardiovasculareventswitharanesptherapytreat